Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

Zepbound tops Wegovy for weight loss in first head-to-head study comparing the drugs

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

Lilly’s Zepbound trims more belly fat than Novo’s Wegovy: Study

Belly fat is linked to a higher risk of diseases such as heart attacks, strokes and diabetes, so doctors recommend that a person’s waistline be no more than half their height.

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study

Key Takeaways

Zepbound beats Wegovy rival in 1st head-to-head weight loss study - National

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

Battle of the weight loss blockbuster drugs: Zepbound beats Wegovy by nearly 50%

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks. Those who took semaglutide — known as Novo Nordisk's Wegovy, lost about 33 pounds.